Document is current
Any future updates will be listed below
-
Authors
Sager, Heinz
Sarr, Anouk
Kuntz, Emmanuelle
Rufener, Lucien
- License Information
-
More Information
Article History
Received: 20 March 2025
Accepted: 14 May 2025
First Online: 6 June 2025
Declarations
:
: Not applicable.
: Not applicable.
: The authors HS and EAK are employees of Elanco Animal Health. In this study, the activity of four isoxazoline-compounds were tested, including molecules from competitors. This comparative study was initiated and funded by Elanco which markets lotilaner under the brand names Credelio™ and AdTab™. The study was run blinded: Invenesis Sàrl received the molecules coded, and the identity of substances being tested on the human and canine GABARs were unknown until the results were discussed.
